The advent of ICIs targeting PD-1/PD-L1 and CTLA-4 axes has transformed the treatment of RCC and UC, with agents like nivolumab and ipilimumab, pembrolizumab, and avelumab being approved in various settings [4,5,30]. The gene discussed is CTLA4; the disease is renal cell carcinoma.